Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : WAND (Milestone Scientific) -- Ignore unavailable to you. Want to Upgrade?

To: CMon who wrote (523)	5/21/1998 8:10:00 AM
From: Mason Barge	Respond to of 717

I don't give a rat's a** how they pay the guy, and it doesn't bother me a bit personally. What bothers me is what this news report is going to do to the price of the stock. ( And for that matter, why HAVEN'T they (in the meantime) paid some neutral lab to run similar tests? The public is going to react poorly to this, IMHO, and it could really hurt the stock price, as there is now a widely-heard built-in criticism to any claim of independent evaluation of the Wand's effectiveness. Paying stock options like this turns the evaluation from an independent test into an in-house test. The researchers are biased as a matter of hard fact. The tests could be 100% accurate, understand, but a researcher with a strong financial incentive to see or promote positive results is not neutral.